8-K: Globalink Amends Merger Deal with Alps Life Sciences

Globalink Investment Inc. and Alps Life Sciences Inc. have amended their merger agreement, adjusting escrow terms and extending the shareholder consent deadline.

Summary

• Globalink Investment Inc. and Alps Life Sciences Inc. (Alps Holdco) entered into a Third Amendment to their Amended and Restated Merger Agreement on September 27, 2025.
• The amendment allows Dr. Tham Seng Kong, in his personal capacity, to contribute all Escrow Shares from his personal entitlement of Merger Consideration Shares.
• The Alps Holdco Shareholder Written Consent Deadline has been extended to be prior to the Effective Time of the merger.
• The Escrow Amount is set at 5% of the total Merger Consideration, with each share valued at $10.00.
• The Escrow Property will serve as the sole source of payment for Alps Holdco Shareholders' obligations under Article XII of the agreement.
• All distributions from the Escrow Account will be treated as an adjustment to Dr. Tham Seng Kong's Merger Consideration Shares.
• Indemnification claims against the Escrow Property are subject to an Expiration Date six months after the Closing Date.

Sentiment

Score: 6

Explanation: The amendment is a procedural step to keep the merger on track, addressing specific terms and deadlines. While the deadline extension could be seen negatively, the overall intent is to facilitate the transaction, suggesting a neutral to slightly positive sentiment that the parties are actively working towards closing.

Positives

• Streamlines the escrow process by designating Dr. Tham Seng Kong as the sole contributor of Escrow Shares, potentially simplifying future claim resolution.
• Extension of the Alps Holdco Shareholder Written Consent Deadline provides additional flexibility for obtaining necessary approvals.

Negatives

• Concentrates the risk associated with the escrow obligations onto a single individual, Dr. Tham Seng Kong.
• The extension of the shareholder consent deadline could indicate challenges or delays in securing shareholder approval for the business combination.

Risks

• The proposed transactions may not be consummated within the anticipated time period, or at all.
• Globalink may fail to obtain stockholder approval of the proposed business combination.
• The parties may fail to secure required regulatory approvals under applicable laws.
• Other conditions to the consummation of the proposed transactions under the Merger Agreement may not be satisfied.
• Termination of the Merger Agreement could lead to a significant decline in Globalink's stock price.
• The announcement or pendency of the proposed transactions may disrupt PubCo's, Globalink's, or Alps Holdco's current plans and operations.
• Inability to recognize the anticipated benefits of the proposed transactions.
• Unexpected costs resulting from the proposed transactions.
• Changes in general economic conditions, regulatory conditions and developments, or applicable laws or regulations.
• The nature, cost, and outcome of pending and future litigation and other legal proceedings related to the proposed transactions.

Future Outlook

The filing indicates a continued effort to progress towards the consummation of the proposed business combination between Globalink and Alps Holdco, with adjustments made to facilitate the process and secure necessary shareholder approvals.

Management Comments

• Each of Globalink, Alps Holdco, and PubCo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Industry Context

This amendment reflects typical procedural adjustments often seen in SPAC business combinations as parties work to finalize terms and meet regulatory and shareholder approval requirements. Such amendments are common in complex merger processes, particularly when dealing with escrow arrangements and shareholder consents.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• General risk of litigation and other legal proceedings related to the proposed transactions.

Related Party Transactions

• Dr. Tham Seng Kong, acting in his personal capacity, will contribute all Escrow Shares from his personal entitlement of Merger Consideration Shares, while also serving as the Seller Representative. This arrangement centralizes the escrow obligations from Alps Holdco shareholders to him.

Stakeholder Impact

• Shareholders (Globalink & Alps Holdco): Directly impacted by the terms of the merger and its eventual consummation or termination. The amendment clarifies escrow terms and extends a key approval deadline.
• Management (Globalink & Alps Holdco): Involved in executing the amended agreement and working towards closing the transaction.
• Regulatory Authorities (SEC): Involved in reviewing the Form F-4 registration statement and other filings related to the proposed transactions.

Next Steps

• Alps Holdco to obtain and deliver the Alps Holdco Shareholder Written Consent prior to the Effective Time.
• PubCo and Globalink to file additional relevant documents with the SEC, including amendments or supplements to the Form F-4 registration statement.
• Globalink's stockholders to vote on the proposed business combination.
• Consummation of the proposed transactions, subject to various conditions including regulatory approvals.

Key Dates

Recommendation

This filing details a procedural amendment to an existing merger agreement, primarily concerning escrow arrangements and an extension for shareholder consent. It does not introduce new financial performance data or significant strategic shifts that would warrant a change in investment recommendation. Investors should hold pending the successful completion of the merger and subsequent operational updates.

Keywords

Globalink Investment, Alps Life Sciences, Merger Agreement, 8-K Filing, Business Combination, SEC Filing, Escrow Shares, Shareholder Consent, Dr. Tham Seng Kong, SPAC